United States

People: Acceleron Pharma Inc (XLRN.O)

XLRN.O on Consolidated Issue listed on NASDAQ Global Market

21 Oct 2016
Change (% chg)

$-0.99 (-3.28%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Knopf, John 

Dr. John L. Knopf is no longer President, Chief Executive Officer, Director of Acceleron Pharma, Inc., with effect from December 1, 2016. He co-founded Acceleron in 2003 and is our Chief Executive Officer and President. Dr. Knopf served on our Board of Directors from 2003 to 2004, and has served from 2007 to the present. Prior to founding Acceleron, Dr. Knopf served as Site Head of the Wyeth Research facilities in Cambridge, MA and Vice President of Metabolic and Respiratory Disease. Dr. Knopf was an early key scientist at Genetics Institute (GI) from 1982 to 1998, where he participated in the development of pioneering biopharmaceutical products including the first treatment for hemophilia, recombinant factor VIII Recombinate® and helped establish GI as a premier biopharmaceutical company. While at GI, he established a structure-based small molecule discovery group. Dr. Knopf is the author of several key scientific manuscripts in the area of signal transduction, and is named as an inventor of several patents. Dr. Knopf received a BS in biology from SUNY Stonybrook and his Ph.D. in biology at SUNY Buffalo.

Basic Compensation

Total Annual Compensation, USD 460,000
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD 278,500
Fiscal Year Total, USD 738,500

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --